1. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia
- Author
-
Constantine S. Tam and Masa Lasica
- Subjects
Continuous therapy ,medicine.medical_specialty ,Hematology ,biology ,business.industry ,Chronic lymphocytic leukemia ,Macroglobulinemia ,X-linked agammaglobulinemia ,medicine.disease ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,Ibrutinib ,Toxicity ,medicine ,Cancer research ,biology.protein ,Bruton's tyrosine kinase ,business ,030215 immunology - Abstract
Bruton tyrosine kinase inhibitors have indisputably transformed the treatment landscape of chronic lymphocytic leukemia, but require continuous therapy to maintain response. This places emphasis on their unique toxicity profile and potential loss of efficacy owing to resistance. Data from single-arm clinical studies are suggestive of comparable efficacy and favorable toxicity profiles of next-generation Bruton tyrosine kinase inhibitors. This is supported by the ASPEN study in Waldenstrom's macroglobulinemia, which convincingly demonstrated that zanubrutinib has a better toxicity profile than ibrutinib. Novel, reversible Bruton tyrosine kinase inhibitors are showing the potential to improve long-term efficacy by overcoming common mechanisms of resistance.
- Published
- 2021